Submit Deal

CATALIO CAPITAL MANAGEMENT

Summary

Catalio Capital Management is a Venture capital investments in breakthrough biomedical technology companies.

Deals Overview

Total Deals26

Valued Deals25

Total Value£ 2.89 B

Avg. Deal Size£ 115 M

Market Context

Senior Management

Jacob Vogelstein
Co-founder and Managing Partner
Edward Mathias
Chairman
George Petrocheilos
Founding Partner

Sort

freenome

HQ - United States

Biotechnology

25 Jun 2019

Investment Date

£ 126 M

Deal Value

atai life sciences

HQ - Germany

Biotechnology

23 Nov 2020

Investment Date

£ 93 M

Deal Value

$fractyl laboratories inc$

fractyl laboratories inc

HQ - United States

Medical Equipment

4 Mar 2020

Investment Date

£ 42 M

Deal Value

hyperfine research inc

HQ - United States

Software

22 Dec 2021

Investment Date

100%

Stake

£ 420 M

Deal Value

dna script

HQ - France

Biotechnology

26 Oct 2021

Investment Date

£ 119 M

Deal Value

dna script

HQ - France

Biotechnology

4 Jan 2022

Investment Date

£ 148 M

Deal Value

affini-t therapeutics

HQ - United States

Biotechnology

22 Mar 2022

Investment Date

£ 132 M

Deal Value

reflexion medical

HQ - United States

Health Care Services

Medical Equipment

10 Mar 2022

Investment Date

£ 60 M

Deal Value

pheast

HQ - United States

Biotechnology

26 Apr 2022

Investment Date

£ 59 M

Deal Value

celsius therapeutics

HQ - United States

Biotechnology

24 Mar 2022

Investment Date

£ 68 M

Deal Value

odyssey therapeutics

HQ - United States

Health Care Services

13 Oct 2022

Investment Date

£ 152 M

Deal Value

metagenomi

HQ - United States

Biotechnology

5 Jan 2023

Investment Date

£ 82 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy